Spots Global Cancer Trial Database for tipifarnib
Every month we try and update this database with for tipifarnib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy | NCT03719690 | HRAS Gene Mutat... HNSCC | Tipifarnib HRAS Detection ... | 18 Years - | Kura Oncology, Inc. | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Subjects With Myelodysplastic Syndromes | NCT02779777 | Myelodysplastic... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | NCT00243035 | Refractory Mult... Stage II Multip... Stage III Multi... | bortezomib tipifarnib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| R115777 in Treating Patients With Advanced Solid Tumors | NCT00025454 | Unspecified Adu... | tipifarnib | 18 Years - | City of Hope Medical Center | |
| Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia | NCT00602771 | Acute Myeloid L... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Secondary Acute... Untreated Adult... | tipifarnib etoposide | 70 Years - | National Cancer Institute (NCI) | |
| Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS) | NCT00050154 | Myelodysplastic... | ZARNESTRA, tipi... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies | NCT04865159 | Advanced Solid ... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT02227901 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | Tipifarnib External Beam R... Temozolomide Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission | NCT00093470 | Acute Myeloid L... Adult Acute Meg... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Myelodysplastic... Recurrent Adult... | Clinical Observ... Tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma | NCT00079339 | Untreated Child... | radiation thera... tipifarnib | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00124644 | Leukemia | cytarabine daunorubicin hy... etoposide tipifarnib chemotherapy enzyme inhibito... high-dose chemo... | 18 Years - 59 Years | National Cancer Institute (NCI) | |
| Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00112853 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Secondary Acute... Untreated Adult... | tipifarnib etoposide | 70 Years - | National Cancer Institute (NCI) | |
| Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery | NCT00281957 | Recurrent Melan... Stage IV Melano... | sorafenib tosyl... tipifarnib temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Patients With Metastatic Malignant Melanoma | NCT00060125 | Recurrent Melan... Stage IV Melano... | tipifarnib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer | NCT00026104 | Adenocarcinoma ... Stage II Pancre... Stage III Pancr... | gemcitabine hyd... paclitaxel tipifarnib radiation thera... | - | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT00027872 | Acute Myeloid L... Adult Acute Bas... Adult Acute Eos... Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Cellular Diagno... Untreated Adult... | tipifarnib laboratory biom... | 65 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | NCT00454480 | Leukemia Myelodysplastic... | alemtuzumab arsenic trioxid... azacitidine busulfan clofarabine cytarabine daunorubicin hy... fludarabine pho... gemtuzumab ozog... melphalan tipifarnib DNA methylation... cytogenetic ana... gene expression... mutation analys... diagnostic labo... immunologic tec... allogeneic hema... nonmyeloablativ... | - | National Cancer Institute (NCI) | |
| R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors | NCT00005990 | Unspecified Adu... | tipifarnib topotecan hydro... | 18 Years - | NYU Langone Health | |
| Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy. | NCT02464228 | Relapsed or Ref... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| Tipifarnib in Treating Patients With Metastatic Malignant Melanoma | NCT00060125 | Recurrent Melan... Stage IV Melano... | tipifarnib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT00027872 | Acute Myeloid L... Adult Acute Bas... Adult Acute Eos... Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Cellular Diagno... Untreated Adult... | tipifarnib laboratory biom... | 65 Years - | National Cancer Institute (NCI) | |
| Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | NCT00070252 | Adult Solid Neo... Inflammatory Br... Male Breast Car... Stage IIIA Brea... Stage IIIB Brea... | Capecitabine Docetaxel Laboratory Biom... Pharmacological... Tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00055757 | Stage IIIB Non-... Stage IV Non-sm... | tipifarnib cisplatin gemcitabine hyd... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia | NCT00040105 | Leukemia, Myelo... | Zarnestra (R115... Gleevec (Imatin... | 16 Years - | M.D. Anderson Cancer Center | |
| Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer | NCT00052728 | Breast Cancer | tamoxifen citra... tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | NCT00470301 | Breast Cancer Male Breast Can... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | tipifarnib paclitaxel doxorubicin cyclophosphamid... | 18 Years - | National Cancer Institute (NCI) | |
| Expanded Access to Tipifarnib | NCT04809233 | HRAS Mutations ... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia | NCT02807272 | Leukemia, Myelo... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma | NCT00005859 | Brain and Centr... | tipifarnib | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors | NCT00005990 | Unspecified Adu... | tipifarnib topotecan hydro... | 18 Years - | NYU Langone Health | |
| Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma | NCT00070525 | Childhood High-... Childhood Oligo... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... | tipifarnib | - 21 Years | National Cancer Institute (NCI) | |
| Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase | NCT00383474 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase Recurrent Adult... Recurrent Adult... Recurrent Disea... Untreated Adult... Untreated Adult... | Bortezomib Laboratory Biom... Tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia | NCT02807272 | Leukemia, Myelo... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | NCT04284774 | Malignant Solid... Recurrent Adren... Recurrent Ectom... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Melan... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Recurrent WHO G... Refractory Adre... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Mela... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory WHO ... | Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Tipifarnib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer | NCT00003707 | Unspecified Adu... | gemcitabine hyd... tipifarnib | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | NCT00470301 | Breast Cancer Male Breast Can... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | tipifarnib paclitaxel doxorubicin cyclophosphamid... | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00058097 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | tipifarnib radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | NCT00335764 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | sorafenib tosyl... erlotinib hydro... tipifarnib temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | NCT00470301 | Breast Cancer Male Breast Can... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | tipifarnib paclitaxel doxorubicin cyclophosphamid... | 18 Years - | National Cancer Institute (NCI) | |
| Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer | NCT00077363 | Recurrent Breas... Stage IV Breast... | tipifarnib capecitabine | 18 Years - | National Cancer Institute (NCI) | |
| R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas | NCT00021541 | Neurofibroma, P... Neurofibromatos... | tipifarnib placebo | 3 Years - 25 Years | National Institutes of Health Clinical Center (CC) | |
| Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | NCT00025480 | Lung Cancer | carboplatin paclitaxel tipifarnib radiation thera... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission | NCT00093470 | Acute Myeloid L... Adult Acute Meg... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Myelodysplastic... Recurrent Adult... | Clinical Observ... Tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT02227901 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | Tipifarnib External Beam R... Temozolomide Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer | NCT00082810 | Estrogen Recept... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | fulvestrant tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | NCT00096122 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Secondary Acute... Secondary Myelo... Untreated Adult... | cytarabine idarubicin tipifarnib | 15 Years - 70 Years | National Cancer Institute (NCI) | |
| Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia | NCT00040105 | Leukemia, Myelo... | Zarnestra (R115... Gleevec (Imatin... | 16 Years - | M.D. Anderson Cancer Center | |
| R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | NCT00005848 | Prostate Cancer | chemotherapy tipifarnib | 18 Years - | Fox Chase Cancer Center | |
| Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | NCT00096122 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Secondary Acute... Secondary Myelo... Untreated Adult... | cytarabine idarubicin tipifarnib | 15 Years - 70 Years | National Cancer Institute (NCI) | |
| Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | NCT00335764 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | sorafenib tosyl... erlotinib hydro... tipifarnib temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Young Patients With Refractory Leukemia | NCT00022451 | Leukemia | tipifarnib | - 21 Years | National Institutes of Health Clinical Center (CC) | |
| Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT00027872 | Acute Myeloid L... Adult Acute Bas... Adult Acute Eos... Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Cellular Diagno... Untreated Adult... | tipifarnib laboratory biom... | 65 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer | NCT00026104 | Adenocarcinoma ... Stage II Pancre... Stage III Pancr... | gemcitabine hyd... paclitaxel tipifarnib radiation thera... | - | National Cancer Institute (NCI) | |
| Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer | NCT00082810 | Estrogen Recept... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | fulvestrant tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | NCT04997902 | HNSCC | Tipifarnib Alpelisib | 18 Years - | Kura Oncology, Inc. | |
| R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer | NCT00005843 | Pancreatic Canc... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer | NCT00054470 | Breast Cancer | trastuzumab tipifarnib | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma | NCT00079339 | Untreated Child... | radiation thera... tipifarnib | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT00027872 | Acute Myeloid L... Adult Acute Bas... Adult Acute Eos... Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Cellular Diagno... Untreated Adult... | tipifarnib laboratory biom... | 65 Years - | National Cancer Institute (NCI) | |
| Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations | NCT02383927 | Thyroid Cancer Squamous Cell C... HRAS Mutant Tum... Other Squamous ... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy | NCT03719690 | HRAS Gene Mutat... HNSCC | Tipifarnib HRAS Detection ... | 18 Years - | Kura Oncology, Inc. | |
| Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer | NCT00077363 | Recurrent Breas... Stage IV Breast... | tipifarnib capecitabine | 18 Years - | National Cancer Institute (NCI) | |
| Expanded Access to Tipifarnib | NCT04809233 | HRAS Mutations ... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer | NCT00077519 | Pancreatic Canc... | tipifarnib radiation thera... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer | NCT00244972 | Advanced Malign... | Laboratory Biom... Sorafenib Tosyl... Tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors | NCT00085553 | Solid Neoplasm | Erlotinib Hydro... Laboratory Biom... Pharmacological... Tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS) | NCT00050154 | Myelodysplastic... | ZARNESTRA, tipi... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer | NCT00077363 | Recurrent Breas... Stage IV Breast... | tipifarnib capecitabine | 18 Years - | National Cancer Institute (NCI) | |
| R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer | NCT00005989 | Lung Cancer | tipifarnib | 18 Years - | Mayo Clinic | |
| Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS | NCT03496766 | Non Small Cell ... | Tipifarnib | - | Spanish Lung Cancer Group | |
| R115777 in Treating Patients With Advanced Bladder Cancer | NCT00006376 | Bladder Cancer Transitional Ce... | chemotherapy tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | NCT00101153 | Leukemia | cytarabine daunorubicin hy... tipifarnib | 56 Years - | University Health Network, Toronto | |
| Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy. | NCT02464228 | Relapsed or Ref... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| Tipifarnib in Treating Patients With Myelodysplastic Syndromes | NCT00005845 | Chronic Myelomo... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... | tipifarnib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia | NCT00004009 | Leukemia | tipifarnib | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00055757 | Stage IIIB Non-... Stage IV Non-sm... | tipifarnib cisplatin gemcitabine hyd... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | NCT01361464 | Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Secondary Acute... Untreated Adult... | Tipifarnib Laboratory Biom... | 65 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
